XNK Therapeutics to use generic name evencaleucel for lead candidate

Corporate Breaking News

Home : XNK Therapeutics to use generic name evencaleucel for lead candidate

Sep 26 2022	XNK Therapeutics to use generic name evencaleucel for lead candidate
HUDDINGE, Sweden, Sept. 26, 2022 /PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced it will adopt the generic name evencaleucel for its lead candidate targeting multiple myeloma. Evencaleucel was recently recommended by the World Health Organization (WHO) as the International...


Source:https://www.prnewswire.com:443/news-releases/xnk-therapeutics-to-use-generic-name-evencaleucel-for-lead-candidate-301632787.html

Related News
» Hyaluronic Acid Raw Material Market Size to Grow by USD 2.87 billion, Need For Safe and Stable Drugs that Require Minimal Monitoring to Boost Market Growth - Technavio » Alpha Glucosidase Inhibitors Market to record USD 567.96 Mn incremental growth -- Driven by increase in awareness of diabetes and growing initiatives